Compare GSK plc (GSK) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs KraneShares Electric Vehicles and Future Mobility — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: GSK plc pays a 3.57% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and GSK plc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| GSK | KARS | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $38.01 |
52-Week Low | $38.22 | $25.59 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
KARS trades at $30.95, down 0.55% today, with a bullish technical signal driven by moving averages and oscillators, though the RSI_6 at 85.22 suggests overbought conditions. Support lies near $30, resistance at $31. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support, though U.S. adoption lags.
The outlook for KARS is supported by accelerating EV adoption globally, but risks include U.S. market hesitation, competitive pressures from Chinese automakers, and potential volatility from geopolitical events. Analyst sentiment is mixed, with technical indicators bullish but valuation metrics unavailable, requiring close monitoring of upcoming financial results for clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
